A new study has raised a safety concern for people using popular GLP-1 medications along with multiple blood pressure medicines. Researchers found that some patients may face a higher risk of dizziness, fainting, falls and dangerously low blood pressure after starting these diabetes and weight-loss drugs.

The study, conducted by researchers at Northwestern Medicine, followed more than 42,000 adults who started GLP-1 medications such as semaglutide, tirzepatide or liraglutide while already taking blood pressure medicines.

Researchers monitored episodes of low blood pressure, including dizziness, fainting, falls, medical diagnoses of hypotension and extremely low blood pressure readings. They found that such events increased from 8.7% to 10.2% within six months of starting GLP-1 therapy. The increased risk continued even after one year.

The risk appeared to be higher among people aged 65 years and above and those living with type 2 diabetes. Researchers also noted that the increased risk could not be explained only by weight loss caused by these medications.

Dr Micah Eimer, senior author of the study and a clinical assistant professor of medicine at Northwestern University Feinberg School of Medicine, said GLP-1 medicines have provided major benefits for many patients but require careful monitoring in certain groups.

“I am a strong supporter of GLP-1 medicines because they are highly effective. However, doctors need to remain alert about possible low blood pressure events in selected patients,” he said.

Dr Eimer also expressed concern about people using GLP-1 medicines without regular medical supervision, especially those who are already taking several blood pressure medications.

GLP-1 drugs have become increasingly popular for managing diabetes and supporting weight loss. However, experts say patients taking these medicines along with blood pressure-lowering drugs may need closer monitoring, as changes in weight, fluid balance and medication effects can influence blood pressure levels.

The findings were presented at ENDO 2026, the annual meeting of the Endocrine Society, held in Chicago. Since the research was presented at a medical meeting, experts note that the findings should be considered preliminary until fully published and reviewed.

Doctors advise patients not to stop or change their medicines without medical guidance but to discuss symptoms such as dizziness, fainting, unusual weakness or falls with their healthcare providers.